

February 6, 2017

Certain Media Coverage Related to ONO Reported on February 4

ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan; President, Representative Director and CEO: Gyo Sagara, “ONO”) announced that the media coverage reported at the Nihon Keizai Shimbun (Nikkei) dated February 4, stating that “ONO has made its policy clear to carry out large-scale acquisitions of about 400 billion yen to 500 billion yen including borrowing in addition to cash on hand within the next five years in the US” is not based on information disclosed by ONO. There is neither the fact that ONO has decided nor the fact that it has been negotiating at present.

ONO considers "expansion of development pipeline" and "promotion of global business expansion" as important management tasks at the present time, and also considers M & A (corporate acquisition) to be one of important options for growth strategy. Regarding M & A, we will determine corporate value and synergy effect in each case. In addition, we regard the scale basically as within the range of cash on hand.

【Expansion of development pipeline】

For sustainable growth, it is essential to expand the development pipeline and continuously deliver new products to the market. To that end, we are promoting open-innovation in drug discovery and accelerating the development of creative and innovative drugs utilizing the world-leading technologies and knowledge. We are also promoting the introduction of new drug candidate compounds through aggressive licensing activities. In addition, we would like to positively consider M & A for unlisted companies holding many attractive new drug candidate compounds and biotech ventures possessing the world-leading technology for drug discovery.

[Promotion of global business expansion]

We are pursuing global clinical development and global business expansion aiming for early launch of our originally created compounds in abroad through out-licensing to overseas partners, so that we can deliver our original new products to patients all over the world.

In addition, we are working to set up our own overseas marketing presence for specialty products such as anticancer drugs, and have already established 100% owned subsidiaries in Korea in 2013 and Taiwan in 2014 to make our own marketing organization there. In the future, we would like to organize our own marketing in Europe and the US.

Contact

ONO PHARMACEUTICAL CO., LTD.

Corporate Communications

public_relations@ono.co.jp